Your browser doesn't support javascript.
loading
Safety, tolerability, and anti-fibrotic efficacy of the CBP/ß-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura, Kiminori; Kanto, Tatsuya; Shimoda, Shinji; Harada, Kenichi; Kimura, Masamichi; Nishikawa, Koji; Imamura, Jun; Ogawa, Eiichi; Saio, Masanao; Ikura, Yoshihiro; Okusaka, Takuji; Inoue, Kazuaki; Ishikawa, Tetsuya; Ieiri, Ichiro; Kishimoto, Junji; Todaka, Koji; Kamisawa, Terumi.
Afiliação
  • Kimura K; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan. Electronic address: kiminori_kimura@tmhp.jp.
  • Kanto T; The Research Center for Hepatitis and Immunology, Gastroenterology Hepatology, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
  • Shimoda S; Department of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
  • Harada K; Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • Kimura M; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Nishikawa K; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Imamura J; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Ogawa E; Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Saio M; Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
  • Ikura Y; Department of Pathology, Takatsuki General Hospital, Osaka, Japan.
  • Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Inoue K; Department of Gastroenterology, International University of Health and Welfare, Narita Hospital, Chiba, Japan.
  • Ishikawa T; Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Aichi, Japan.
  • Ieiri I; Department of Clinical Pharmacokinetics, Division of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • Kishimoto J; Department of Clinical Research Promotion, Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
  • Todaka K; Department of Clinical Research Promotion, Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
  • Kamisawa T; Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
EBioMedicine ; 80: 104069, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35605429
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Hepatite C / Herpesvirus Cercopitecino 1 / Hepatite C Crônica / Doença Hepática Terminal Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: EBioMedicine Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Hepatite C / Herpesvirus Cercopitecino 1 / Hepatite C Crônica / Doença Hepática Terminal Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: EBioMedicine Ano de publicação: 2022 Tipo de documento: Article